NASDAQ:ATRCAtriCure Stock Price, Forecast & News

$44.94

-2.00 (-4.26 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$44.73

Now: $44.94▼

$46.97

50-Day Range

$36.25

MA: $43.82▼

$50.97

52-Week Range

$22.57

Now: $44.94▼

$51.76

Volume428,003 shs

Average Volume481,016 shs

Market Capitalization$1.80 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.8

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Beat the Market (BTM) Rank^™

2.4 Analyst's Opinion

Consensus Rating
AtriCure has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.22, AtriCure has a potential upside of 2.9% from its current price of $44.94.
Amount of Analyst Coverage
AtriCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
AtriCure has received 479 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AtriCure has received 350 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AtriCure has received 57.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote “Outperform” if you believe ATRC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AtriCure does not currently pay a dividend.
Dividend Growth
AtriCure does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,169,280.00 in company stock.
Percentage Held by Insiders
Only 5.80% of the stock of AtriCure is held by insiders.
Percentage Held by Institutions
89.93% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AtriCure are expected to grow in the coming year, from ($1.70) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AtriCure is -37.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AtriCure is -37.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AtriCure has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.39 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:ATRC

Previous Symbol

CUSIP04963C20

CIK1323885

Webwww.atricure.com

Phone513-755-4100

Debt

Debt-to-Equity Ratio0.32

Current Ratio3.25

Quick Ratio2.43

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$230.81 million

Price / Sales7.80

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.25 per share

Price / Book7.19

Profitability

EPS (Most Recent Fiscal Year)($1.07)

Net Income$-35,190,000.00

Net Margins-19.98%

Return on Equity-19.19%

Return on Assets-9.40%

Miscellaneous

Employees620

Outstanding Shares40,073,000

Market Cap$1.80 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

How has AtriCure's stock been impacted by COVID-19 (Coronavirus)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 27.4% and is now trading at $44.94. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AtriCure?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for AtriCure.

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) released its earnings results on Wednesday, April, 29th. The medical device company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.01. The medical device company had revenue of $53.20 million for the quarter, compared to the consensus estimate of $54.13 million. AtriCure had a negative return on equity of 19.19% and a negative net margin of 19.98%. The business's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) earnings per share. View AtriCure's earnings history.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $53.2-53.2 million, compared to the consensus revenue estimate of $59.84 million.

What price target have analysts set for ATRC?

9 Wall Street analysts have issued 12-month price targets for AtriCure's shares. Their forecasts range from $30.00 to $56.00. On average, they expect AtriCure's stock price to reach $46.22 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View analysts' price targets for AtriCure.

Has AtriCure been receiving favorable news coverage?

Media headlines about ATRC stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AtriCure earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAtriCure.

Who are some of AtriCure's key competitors?

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), Allergan (AGN), CVS Health (CVS), Walt Disney (DIS) and Intel (INTC).

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.75%), Wellington Management Group LLP (5.06%), Champlain Investment Partners LLC (4.23%), Invesco Ltd. (3.83%), Fred Alger Management LLC (3.15%) and GW&K Investment Management LLC (2.67%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View institutional ownership trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Peregrine Capital Management LLC, BlackRock Inc., GW&K Investment Management LLC, The Manufacturers Life Insurance Company , Paradigm Capital Management Inc. NY, DAFNA Capital Management LLC, and Eagle Asset Management Inc.. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, and Michael H Carrel. View insider buying and selling activity for AtriCure.

Which institutional investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Invesco Ltd., Orbimed Advisors LLC, Champlain Investment Partners LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Nuveen Asset Management LLC, and Granahan Investment Management Inc. MA. View insider buying and selling activity for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $44.94.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.80 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 6/2/2020 by MarketBeat.com Staff